Evidence map›Paper›PMID 36769406›Full record

ArticleJournal of clinical medicine2023

Computational Simulation Model to Predict Behavior Changes in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Analysis of Two Regional Japanese Populations.

Gen Suzuki, Ryuichi Iwakiri, Eri Udagawa, Sindy Ma, Ryoko Takayama, Hiroshi Nishiura, Koshi Nakamura, Samuel P Burns, Paul Michael D'Alessandro, Jovelle Fernandez

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gen SuzukiJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo 103-8668, Japan.
Ryuichi IwakiriJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo 103-8668, Japan.
Eri UdagawaJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo 103-8668, Japan.
Sindy MaPricewaterhouseCoopers Advisory Services LLC, Philadelphia, PA 19103, USA.
Ryoko TakayamaPricewaterhouseCoopers Consulting LLC, Tokyo 100-0004, Japan.
Hiroshi NishiuraHealth & Environment Science, Kyoto University, Kyoto 606-8601, Japan.ORCID 0000-0003-0941-8537
Koshi NakamuraDepartment of Public Health and Hygiene, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan.ORCID 0000-0001-8141-7614
Samuel P BurnsPricewaterhouseCoopers Advisory Services LLC, Philadelphia, PA 19103, USA.
Paul Michael D'AlessandroPricewaterhouseCoopers Advisory Services LLC, Philadelphia, PA 19103, USA.
Jovelle FernandezJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo 103-8668, Japan.

Funding

PwC Consulting LLC N/ATakeda Pharmaceuticals Company Limited N/A
6 · The paper itself

Abstract

Managing inflammatory bowel disease (IBD) is a major challenge for physicians and patients during the COVID-19 pandemic. To understand the impact of the pandemic on patient behaviors and disruptions in medical care, we used a combination of population-based modeling, system dynamics simulation, and linear optimization. Synthetic IBD populations in Tokyo and Hokkaido were created by localizing an existing US-based synthetic IBD population using data from the Ministry of Health, Labor, and Welfare in Japan. A clinical pathway of IBD-specific disease progression was constructed and calibrated using longitudinal claims data from JMDC Inc for patients with IBD before and during the COVID-19 pandemic. Key points considered for disruptions in patient behavior (demand) and medical care (supply) were diagnosis of new patients, clinic visits for new patients seeking care and diagnosed patients receiving continuous care, number of procedures, and the interval between procedures or biologic prescriptions. COVID-19 had a large initial impact and subsequent smaller impacts on demand and supply despite higher infection rates. Our population model (Behavior Predictor) and patient treatment simulation model (Demand Simulator) represent the dynamics of clinical care demand among patients with IBD in Japan, both in recapitulating historical demand curves and simulating future demand during disruption scenarios, such as pandemic, earthquake, and economic crisis.

Indexed as

biologicscomputer simulationCOVID-19Crohn’s diseaseinflammatory bowel diseasepandemiculcerative colitis

Identifiers

PMID36769406
PMCPMC9917920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.